Nasdaq

Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis

SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) approved ...
Nasdaq

Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older

Despite being the most common vaginal condition,1 BV symptoms are often mistaken for a yeast infection2 JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a ...
Monthly Prescribing Reference

Xaciato Vaginal Gel for Bacterial Vaginosis Now Available

The product is administered via a user-filled disposable applicator delivering 5g of gel containing 100mg of clindamycin as a single dose. Xaciato ™ (clindamycin phosphate) vaginal gel 2% is now ...
Monthly Prescribing Reference

Xaciato Vaginal Gel Approved for Bacterial Vaginosis

Credit: Getty Images. Xaciato, a lincosamide antibacterial, is a thermosetting bioadhesive hydrogel containing clindamycin phosphate 2%. The Food and Drug Administration (FDA) has approved Xaciato™ ...
Business Wire

Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and ...

JERSEY CITY, N.J. & SAN DIEGO--(BUSINESS WIRE)--Organon (NYSE: OGN), a global women’s healthcare company, and Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today ...